The critical path for the network activities shown below is ________ with duration ________.ActivityDurationPredecessorsA4-B2AC7-D4AE5B, C, D

You are examining a patient who presents with the chief complaint of excessive sweating,. The patient states, “I sure sweat a lot, especially on my face and feet but it doesn’t have an odor.” The nurse practitioner knows this data belongs in which portion of the SOAP note:

A 73 year old male patient presents with an indurated and crusted papule that has been growing slowly over the past year on his right ear.  No pearly borders or telangiectases are noted. It is painless and essentially asymptomatic.  The nurse practitioner suspects 

What is the output for the following program:  

Your patient is pregnant. This was established through a quantitative serum hCG one week ago. Your patient reports she has experienced “a little bit of bleeding” over the past two days.  Which testing should you complete to help determine the cause?

Select the correct output for the following code snippet.Assume:push() − adds a data element to the top of the stack.pop()   − removes a data element from the top of the stack.IsEmpty() – checks if the stack is Empty 

In the paper by Freed in Cell the authors described a signaling difference for EGF versus EREG. What was the difference and describe two techniques that were used and how they supported the observation.

Name two upstream signaling pathways that can activate canonical NF-kB signaling.

You are studying a newly described receptor called GPR100. Your collaborators have circumstantial physiological data in mice suggesting that this receptor can activate PLCb (leading to Ca++ release from intracellular stores) and can also activate ERK-MAP. You have screened for ligands that bind to GPR100 and found two molecules that binds to the receptor and you termed them UC2024 and UC2025. You know nothing about how UC2024 and UC2025 may affect GPR100 signaling. Design experiments to determine if UC2024 and UC2025 function as an agonist, antagonist, or inverse agonist and also design experiments to determine if these ligands are biased in any way?

BCL-3 is an atypical (noncanonical) IkappaB molecule. Provide two reasons below as to why BCL-3 is considered an atypical IkappaB.